Almasry Pharmacy

Bedremine 50 Mg 30 Tablets

Short Description:
Bedremine 50 mg 30 tablets contains desvenlafaxine, an SNRI antidepressant used for the treatment of major depressive disorder (MDD) in adults. The extended-release formulation provides once-daily dosing to help improve mood, energy, and overall daily functioning under medical supervision.

EGP 90

Out of Stock
We'll message you as soon as it's back in stock.
delivery-iconDelivery to governorates within 3-4 working days
refund-iconEasy returns within 14 days
Specifications
SKUISG000519
BrandبيدريمينLink Icon
Categories
Medication & Treatments
Concentrations
50 Mg
Shop by ConcernsAnxiety with DepressionLink Icon, Loss of InterestLink Icon, Low MoodLink Icon, Major Depressive DisorderLink Icon
Gender
Neutral
Shop By GoalsDepression ManagementLink Icon, Mental PerformanceLink Icon, Mood StabilizationLink Icon
Imported Or LocalLocal
Ingredient
Desvenlafaxine
UPC
6222001401653
Product Form
Tablets
Specialty
Clinically Tested
Extended Release
Prescription only
Sub Categories
Anti Depressants
Unit Count
30 Tablets
Warning
Do Not Use With MAOIs
May increase blood pressure
Possible Serotonin Syndrome
Risk of suicidal thoughts
Use under medical supervision only
About the product›

Bedremine 50 Mg 30 Tablets

Description:

Bedremine 50 mg is a prescription antidepressant medicine containing desvenlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI). It is formulated as extended-release tablets for once-daily dosing to help manage symptoms of major depressive disorder (MDD) in adults. By balancing key brain chemicals (serotonin and norepinephrine), Bedremine 50 mg can improve mood, energy, concentration, and overall daily functioning in patients with depression. This product is intended for use under medical supervision only.


Indications:

  • Treatment of major depressive disorder (MDD) in adults.
  • Helps reduce persistent low mood, sadness, and feelings of hopelessness associated with depression.
  • Improves lack of interest or pleasure in daily activities (anhedonia).
  • Helps manage associated symptoms such as fatigue, low energy, poor concentration, and changes in appetite or sleep patterns related to MDD.
  • Supports overall emotional stability and functioning as part of a comprehensive depression management plan prescribed by a healthcare professional.

Active Ingredients / Key Components:

  • Desvenlafaxine (as desvenlafaxine succinate) – 50 mg per extended-release tablet.
  • Other inactive ingredients (excipients) are present to form the extended-release tablet core and coating; detailed excipient list and their concentrations , please check the product leaflet or the manufacturer’s official website. Please refer to the official package insert for full composition.

Dosage & Administration / How to Use:

  • Bedremine 50 mg is for oral use only and should be taken exactly as prescribed by your doctor.
  • Usual adult starting dose: 50 mg once daily, preferably at the same time each day. Do not change your dose without consulting your physician.
  • Swallow the extended-release tablet whole with a glass of water. Do not crush, chew, split, or dissolve the tablet, as this may affect the extended-release properties and increase side effects.
  • Can be taken with or without food. Taking it with food may help reduce gastrointestinal discomfort in some patients.
  • If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not take a double dose to make up for a missed dose.
  • Treatment duration should be determined by your doctor. Antidepressants often require several weeks of continuous use before full benefit is observed. Do not stop taking Bedremine suddenly without medical advice.
  • To discontinue, your doctor may gradually reduce the dose to minimize withdrawal (discontinuation) symptoms.

Clinical Benefits:

  • Helps restore balance of serotonin and norepinephrine in the brain, which are key neurotransmitters involved in mood regulation.
  • Reduces core symptoms of major depressive disorder, including persistent sadness, low mood, and loss of interest in normal activities.
  • May improve energy levels, motivation, and ability to carry out daily tasks in patients with depression.
  • Supports better concentration, cognitive function, and overall mental performance impaired by depressive symptoms.
  • Extended-release formulation allows convenient once-daily dosing and more stable blood levels throughout the day.
  • Can be used as part of a comprehensive treatment plan that may include psychotherapy and lifestyle modifications, as directed by a healthcare professional.

Warnings & Contraindications:

  • Contraindicated in patients with known hypersensitivity to desvenlafaxine, venlafaxine, or any component of the formulation.
  • Do not use concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI. Allow at least 7 days after stopping desvenlafaxine before starting an MAOI, or follow your doctor’s specific instructions.
  • Antidepressants may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults, especially at the beginning of treatment or when the dose is changed. Close monitoring by caregivers and healthcare professionals is essential.
  • Use with caution in patients with a history of bipolar disorder, mania, seizures, glaucoma (especially narrow-angle), cardiovascular disease, hypertension, or bleeding disorders.
  • Desvenlafaxine may increase blood pressure and heart rate; regular monitoring is recommended, particularly in patients with pre-existing hypertension or cardiovascular conditions.
  • May increase the risk of bleeding, especially when used with anticoagulants, antiplatelet agents, or NSAIDs. Inform your doctor about all medicines you are taking.
  • Serotonin syndrome, a potentially life-threatening condition, may occur when used with other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tramadol, St. John’s wort). Seek immediate medical attention if symptoms such as agitation, confusion, rapid heart rate, fever, muscle stiffness, or tremor occur.
  • Use with caution in patients with kidney or liver impairment; dose adjustment may be required as directed by a physician.
  • Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. The potential benefits and risks must be carefully evaluated.
  • May cause drowsiness, dizziness, or blurred vision in some patients. Avoid driving or operating machinery until you know how the medicine affects you.
  • Avoid alcohol consumption while taking Bedremine, as it may increase side effects such as dizziness and impaired judgment.
  • Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision.
  • Keep out of reach of children.

Side Effects:
  • Common side effects may include nausea, dry mouth, dizziness, headache, insomnia or sleep disturbances, increased sweating, constipation, decreased appetite, and fatigue.
  • Some patients may experience increased blood pressure, palpitations, or changes in heart rate; regular monitoring is advised.
  • Sexual side effects such as decreased libido, delayed ejaculation, or difficulty achieving orgasm may occur.
  • Other possible effects include anxiety, agitation, tremor, blurred vision, and urinary difficulties.
  • Serious side effects (seek immediate medical attention): signs of serotonin syndrome (agitation, confusion, fever, muscle rigidity, rapid heartbeat), severe allergic reactions (rash, itching, swelling of face or throat, difficulty breathing), severe or persistent mood changes, suicidal thoughts, seizures, or significant increase in blood pressure.
  • Discontinuation symptoms (if stopped abruptly) may include dizziness, irritability, nausea, headache, sensory disturbances, or sleep problems. Always follow your doctor’s instructions when stopping treatment.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack or container tightly closed. Do not store above the temperature recommended on the package (typically below 30°c, if specified on the label). Keep out of reach of children.


Specifications:
  • Product type: Prescription antidepressant medicine (SNRI).
  • Active ingredient strength: desvenlafaxine 50 mg per extended-release tablet.
  • Form: Extended-release tablet.
  • Pack size: 30 tablets per pack.
  • Intended use: Adult patients diagnosed with major depressive disorder, under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.

Product Reviews

Overall Rating
0

Based on 0 reviews

Warning iconYou can add a rating once you purchase the product through the My Orders page

Customer Reviews
No reviews yet
TelegramWhatsApp